AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Clearmind Medicine Inc. Common Shares
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00KWY2X19
5.87▼ 0.13 (-2.17%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
—
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
6.00
Day's Range
5.87 – 6.26
52-Week Range
0.07 – 7.16
Volume
8,341
Avg Volume
123.7K
Share Statistics
Shares Outstanding
Employees
2
Exchange
XNAS
Listed
2021-08-10
Share count as of January 19, 2026

Clearmind Medicine Inc. Common Shares (CMND) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Clearmind Medicine Inc. Common Shares (CMND)
What is Clearmind Medicine Inc. Common Shares's Market Cap?
Clearmind Medicine Inc. Common Shares's Market Cap is $927.9K, based on as-reported figures from SEC (XBRL) filings.
What is Clearmind Medicine Inc. Common Shares's Enterprise Value?
Clearmind Medicine Inc. Common Shares's Enterprise Value is -$8.3M, based on as-reported figures from SEC (XBRL) filings.
What is Clearmind Medicine Inc. Common Shares's Net Income (TTM)?
Clearmind Medicine Inc. Common Shares's Net Income (TTM) is -$6.6M, based on as-reported figures from SEC (XBRL) filings.
What is Clearmind Medicine Inc. Common Shares's Diluted EPS (TTM)?
Clearmind Medicine Inc. Common Shares's Diluted EPS (TTM) is -42.00, based on as-reported figures from SEC (XBRL) filings.
What is Clearmind Medicine Inc. Common Shares's Net Debt?
Clearmind Medicine Inc. Common Shares's Net Debt is -$9.3M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · CMNDAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands, except per-share data)
Source: Akyla.ai
Line ItemJul 31, 2026Jul 31, 2025
Operating expenses
General and administrative
Research and development, net
Total operating expenses
Finance income (expenses)
Changes in fair value of derivative warrant liabilities (Note 5)
Changes in fair value of short-term investments (Note 3)
Foreign exchange gain (loss)
Other finance expenses
Interest income on deposits
Changes in fair value of convertible loans (Note 6)
Total finance income
Loss before taxes
Tax expenses
Net Loss and Comprehensive loss